ArticleNature2025
Structure of apolipoprotein B100 bound to the low-density lipoprotein receptor.
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Low-Density Lipoprotein Receptor-Targeted Biomimetic Nanoplatform Suppresses Glioblastoma Stemness and Remodels Antitumor Immunity via Dual Metabolic Disruption.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- When Lipid-Lowering Therapy Fails: Lessons From Functional Genomics and Precision Lipidology.JACC. Case reports · 2026Article
- Apolipoprotein B100 and white matter hyperintensity as distinct mediators of thrombolytic response in acute stroke: preliminary findings.Journal of thrombosis and thrombolysis · 2026Article
- Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy.Molecular cell · 2026Article
- Confidence-guided cryo-EM map optimisation with LocScale-2.0.Nature communications · 2026Article
- The Spectrum of Genetic Causes of Familial Hypercholesterolemia Phenotype.Current atherosclerosis reports · 2026Review
- The N-terminus of apolipoprotein B mediates the interaction of atherogenic lipoproteins with endothelial cells.The Journal of clinical investigation · 2026Article
- Century of Progress on the Structure of APOB-100 in Atherogenic Lipoproteins.Circulation research · 2026Review
- Triglyceride-Rich Lipoprotein Metabolism and Cardiovascular Risk in Diabetes: Bedside to Bench to Bedside.Circulation research · 2026Review
- The low-density lipoprotein receptor LDLR mediates cellular entry of nonenveloped hepatitis A virus.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Emerging Lipid Risk: Lipoprotein(a).Korean circulation journal · 2026Review
- Effect of HDL disk and LDL dimer presence on lipoprotein particle number determination and subclassification.Analytical and bioanalytical chemistry · 2026Article
- New Methods for Calculating LDL-Cholesterol and Related Biomarkers of Atherosclerotic Cardiovascular Disease Risk.Current atherosclerosis reports · 2026Review
- The functional landscape of coding variation in the familial hypercholesterolemia geneScience (New York, N.Y.) · 2026Article
- Metabolic phenotyping of sepsis in large multicenter cohorts: identification of a reproducible high-risk subgroup.Lipids in health and disease · 2026Article
- Cathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver.Science China. Life sciences · 2026Article
- A de novo LDLR mutation in severe familial hypercholesterolemia: case report, functional characterization, and a personalized gene correction strategy exploration.Frontiers in cardiovascular medicine · 2026Article
- Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers.Frontiers in cardiovascular medicine · 2026Review
- Current and Emerging Issues in Familial Hypobetalipoproteinemia-related Steatotic Liver Diseases.Journal of clinical and translational hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein B100 (apoB100) is a structural component of low-density lipoprotein (LDL) and a ligand for the LDL receptor (LDLR)
Indexed as
Identifiers
39663455What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.